Synergistic effect of glucocorticoids and IGF-1 on myogenic differentiation through the Akt/GSK-3β pathway in C2C12 myoblasts

References

• Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79:
   PubMed Web of Science ®Google Scholar
• Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251–267.
   PubMed Web of Science ®Google Scholar
• Wong BL, Rybalsky I, Shellenbarger KC, et al. Long-term outcome of interdisciplinary management of patients with duchenne muscular dystrophy receiving daily glucocorticoid treatment. J Pediatr. 2017;182:296–303.
   PubMed Web of Science ®Google Scholar
• McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451–461.
   PubMed Web of Science ®Google Scholar
• Gloss D, Moxley RT, Ashwal S, et al. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465–472.
   PubMed Web of Science ®Google Scholar
• McRae N, Forgan L, McNeill B, et al. Glucocorticoids improve myogenic differentiation in vitro by suppressing the synthesis of versican, a transitional matrix protein overexpressed in dystrophic skeletal muscles. Int J Mol Sci. 2017;18(12):2629.
   Web of Science ®Google Scholar
• Ma Z, Zhong Z, Zheng Z, et al. Inhibition of glycogen synthase kinase-3β attenuates glucocorticoid-induced suppression of myogenic differentiation in vitro. PLoS One. 2014;9(8):e105528.
   PubMed Web of Science ®Google Scholar
• Belanto JJ, Diaz-Perez SV, Magyar CE, et al. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord. 2010;20(2):111–121.
   PubMed Web of Science ®Google Scholar
• Kim J, Park MY, Kim HK, et al. Cortisone and dexamethasone inhibit myogenesis by modulating the AKT/mTOR signaling pathway in C2C12. Biosci Biotechnol Biochem. 2016;80(11):1–7.
   PubMed Web of Science ®Google Scholar
• Morgan JE, Partridge TA. Muscle satellite cells. Int J Biochem Cell Biol. 2003;35(8):1151–1156.
   PubMed Web of Science ®Google Scholar
• Duan C, Ren H, Gao S. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol. 2010;167(3):344–351.
   PubMed Web of Science ®Google Scholar
• Weintraub H. The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell. 1993;75(7):1241–1244.
   PubMed Web of Science ®Google Scholar
• Powellbraxton L, Hollingshead P, Warburton C, et al. IGF-I is required for normal embryonic growth in mice. Genes Dev. 1993;7(12):2609–2617.
   PubMed Web of Science ®Google Scholar
• Yu M, Wang H, Xu Y, et al. Insulin-like growth factor-1 (IGF-1) promotes myoblast proliferation and skeletal muscle growth of embryonic chickens via the PI3K/Akt signalling pathway. Cell Biol Int. 2015;39(8):910–922.
   PubMed Web of Science ®Google Scholar
• Bodine SC, Furlow JD. Glucocorticoids and skeletal muscle. Adv Exp Med Biol. 2015;872:145–176.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Smith RJ. Dexamethasone enhances insulin-like growth factor-I effects on skeletal muscle cell proliferation. Role of specific intracellular signaling pathways. J Clin Invest. 1995;96(3):1473–1483.
   PubMed Web of Science ®Google Scholar
• Schakman O, Kalista S, Bertrand L, et al. Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology. 2008;149(8):3900–3908.
   PubMed Web of Science ®Google Scholar
• Aj G-B, Jg W, Jb C, et al. Glycogen synthase kinase 3β-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol. 2008;28(24):7309–7322.
   PubMed Web of Science ®Google Scholar
• Xu Q, Wu Z. The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells. J Biol Chem. 2000;275(47):36750–36757.
   PubMed Web of Science ®Google Scholar
• van der Velden JL, Schols AM, Willems J, et al. Glycogen synthase kinase 3 suppresses myogenic differentiation through negative regulation of NFATc3. J Biol Chem. 2008;283(1):358–366.
   PubMed Web of Science ®Google Scholar
• Te Pas MFW, de Jong PR, Verburg FJ. Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family. Mol Biol Rep. 2000;27(2):87–98.
   PubMed Web of Science ®Google Scholar
• Bruscoli S, Donato V, Velardi E, et al. Glucocorticoid-induced leucine zipper (GILZ) and long GILZ inhibit myogenic differentiation and mediate anti-myogenic effects of glucocorticoids. J Biol Chem. 2010;285(14):10385–10396.
   PubMed Web of Science ®Google Scholar
• Pansters NA, Langen RC, Wouters EF, et al. Synergistic stimulation of myogenesis by glucocorticoid and IGF-I signaling. J Appl Physiol. 2013;114(9):1329–1339.
   PubMed Web of Science ®Google Scholar
• Verhees KJ, Schols AM, Kelders MC, et al. Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. Am J Physiol Cell Physiol. 2011;301(5):C995–C1007.
   PubMed Web of Science ®Google Scholar
• van der Velden JL, Langen RC, Kelders MC, et al. Inhibition of glycogen synthase kinase-3β activity is sufficient to stimulate myogenic differentiation. Am J Physiol Cell Physiol. 2006;290(2):C453–C462.
   PubMed Web of Science ®Google Scholar
• Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351(6271):403–407.
   PubMed Web of Science ®Google Scholar
• Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17(5):445–455.
   PubMed Web of Science ®Google Scholar
• Kim S, Zhu Y, Romitti PA, et al. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy. Neuromuscul Disord. 2017;27(8):730–737.
   PubMed Web of Science ®Google Scholar
• Dekelbab BH, Witchel SF, Defranco DB. TNF-alpha and glucocorticoid receptor interaction in L6 muscle cells: a cooperative downregulation of myosin heavy chain. Steroids. 2007;72(9-10):705–712.
   PubMed Web of Science ®Google Scholar
• Han DS, Yang WS, Kao TW. Dexamethasone treatment at the myoblast stage enhanced C2C12 myocyte differentiation. Int J Med Sci. 2017;14(5):434–443.
   PubMed Web of Science ®Google Scholar
• Lang CH, Nystrom GJ, Frost RA. Burn-induced changes in IGF-I and IGF-binding proteins are partially glucocorticoid dependent. Am J Physiol Regul Integr Comp Physiol. 2002;282(1):R207–215.
   PubMed Web of Science ®Google Scholar
• Li BG, Hasselgren PO, Fang CH. Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in cultured L6 myotubes through PI3K/Akt/GSK-3beta and PI3K/Akt/mTOR-dependent mechanisms. Int J Biochem Cell Biol. 2005;37(10):2207–2216.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kumakawa K, Usami S, et al. A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment. BMC Med. 2014;12(1):219.
   PubMed Web of Science ®Google Scholar
• Ciciliot S, Schiaffino S. Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications. Curr Pharm Des. 2010;16(8):906–914.
   PubMed Web of Science ®Google Scholar
• Yu X, Zhang Y, Li T, et al. Long non-coding RNA Linc-RAM enhances myogenic differentiation by interacting with MyoD. Nat Commun. 2017;8(1):14016.
   PubMed Web of Science ®Google Scholar
• Olson EN. Signal transduction pathways that regulate skeletal muscle gene expression. Mol Endocrinol. 1993;7(11):1369–1378.
   PubMedGoogle Scholar
• Tanaka K, Sato K, Yoshida T, et al. Evidence for cell density affecting C2C12 myogenesis: possible regulation of myogenesis by cell-cell communication. Muscle Nerve. 2011;44(6):968–977.
   PubMed Web of Science ®Google Scholar
• Stevenslapsley JE, Ye F, Liu M, et al. Impact of viral-mediated IGF-I gene transfer on skeletal muscle following cast immobilization. Am J Physiol Endocrinol Metab. 2010;299(5):E730–E740.
   PubMed Web of Science ®Google Scholar
• Litwiniuk A, Pijet B, Pijet-Kucicka M, et al. FOXO1 and GSK-3β are main targets of insulin-mediated myogenesis in C2C12 muscle cells. PLoS One. 2016;11(1):e0146726.
   PubMed Web of Science ®Google Scholar
• Jl VDV, Langen RC, Kelders MC, et al. Myogenic differentiation during regrowth of atrophied skeletal muscle is associated with inactivation of GSK-3beta. Am J Physiol Cell Physiol. 2007;292(5):C1636–C1644.
   PubMed Web of Science ®Google Scholar
• Weng J, Wang YH, Li M, et al. GSK3β inhibitor promotes myelination and mitigates muscle atrophy after peripheral nerve injury. Neural Regen Res. 2018;13(2):324–330.
   PubMed Web of Science ®Google Scholar
• Du WJ, Li JK, Wang QY, et al. Lithium chloride preconditioning optimizes skeletal myoblast functions for cellular cardiomyoplasty in vitro via glycogen synthase kinase-3beta/beta-catenin signaling. Cells Tissues Organs. 2009;190(1):11–19.
   PubMed Web of Science ®Google Scholar